Literature DB >> 16717184

Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis.

Jianqiang Mao1, Francesco J DeMayo, Huiguang Li, Lutfi Abu-Elheiga, Ziwei Gu, Tattym E Shaikenov, Parichher Kordari, Subrahmanyam S Chirala, William C Heird, Salih J Wakil.   

Abstract

In animals, liver and white adipose are the main sites for the de novo fatty acid synthesis. Deletion of fatty acid synthase or acetyl-CoA carboxylase (ACC) 1 in mice resulted in embryonic lethality, indicating that the de novo fatty acid synthesis is essential for embryonic development. To understand the importance of de novo fatty acid synthesis and the role of ACC1-produced malonyl-CoA in adult mouse tissues, we generated liver-specific ACC1 knockout (LACC1KO) mice. LACC1KO mice have no obvious health problem under normal feeding conditions. Total ACC activity and malonyl-CoA levels were approximately 70-75% lower in liver of LACC1KO mice compared with that of the WT mice. In addition, the livers of LACC1KO mice accumulated 40-70% less triglycerides. Unexpectedly, when fed fat-free diet for 10 days, there was significant up-regulation of PPARgamma and several enzymes in the lipogenic pathway in the liver of LACC1KO mice compared with the WT mice. Despite the significant up-regulation of the lipogenic enzymes, including a >2-fold increase in fatty acid synthase mRNA, protein, and activity, there was significant decrease in the de novo fatty acid synthesis and triglyceride accumulation in the liver. However, there were no significant changes in blood glucose and fasting ketone body levels. Hence, reducing cytosolic malonyl-CoA and, therefore, the de novo fatty acid synthesis in the liver, does not affect fatty acid oxidation and glucose homeostasis under lipogenic conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717184      PMCID: PMC1570106          DOI: 10.1073/pnas.0603115103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.

Authors:  M Matsuda; B S Korn; R E Hammer; Y A Moon; R Komuro; J D Horton; J L Goldstein; M S Brown; I Shimomura
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

2.  Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene.

Authors:  J Yang; J L Goldstein; R E Hammer; Y A Moon; M S Brown; J D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  The subcellular localization of acetyl-CoA carboxylase 2.

Authors:  L Abu-Elheiga; W R Brinkley; L Zhong; S S Chirala; G Woldegiorgis; S J Wakil
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

4.  Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.

Authors:  L Abu-Elheiga; M M Matzuk; K A Abo-Hashema; S J Wakil
Journal:  Science       Date:  2001-03-30       Impact factor: 47.728

5.  CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.

Authors:  Charles E Chandler; Donald E Wilder; Judith L Pettini; Yvette E Savoy; Stephen F Petras; George Chang; John Vincent; H James Harwood
Journal:  J Lipid Res       Date:  2003-07-01       Impact factor: 5.922

6.  Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero.

Authors:  Subrahmanyam S Chirala; Hua Chang; Martin Matzuk; Lutfi Abu-Elheiga; Jianqiang Mao; Kathleen Mahon; Milton Finegold; Salih J Wakil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

Review 7.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

Authors:  David B Savage; Cheol Soo Choi; Varman T Samuel; Zhen-Xiang Liu; Dongyan Zhang; Amy Wang; Xian-Man Zhang; Gary W Cline; Xing Xian Yu; John G Geisler; Sanjay Bhanot; Brett P Monia; Gerald I Shulman
Journal:  J Clin Invest       Date:  2006-02-16       Impact factor: 14.808

9.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance.

Authors:  Jie An; Deborah M Muoio; Masakazu Shiota; Yuka Fujimoto; Gary W Cline; Gerald I Shulman; Timothy R Koves; Robert Stevens; David Millington; Christopher B Newgard
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

10.  Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets.

Authors:  Lutfi Abu-Elheiga; Wonkeun Oh; Parichher Kordari; Salih J Wakil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

View more
  109 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

2.  Targeting cellular fatty acid synthesis limits T helper and innate lymphoid cell function during intestinal inflammation and infection.

Authors:  Panagiota Mamareli; Friederike Kruse; Chia-Wen Lu; Melanie Guderian; Stefan Floess; Katharina Rox; David S J Allan; James R Carlyle; Mark Brönstrup; Rolf Müller; Luciana Berod; Tim Sparwasser; Matthias Lochner
Journal:  Mucosal Immunol       Date:  2020-04-30       Impact factor: 7.313

3.  Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation.

Authors:  Donald B Jump; Moises Torres-Gonzalez; L Karl Olson
Journal:  Biochem Pharmacol       Date:  2010-12-22       Impact factor: 5.858

Review 4.  Polyunsaturated fatty acid metabolism in prostate cancer.

Authors:  Isabelle M Berquin; Iris J Edwards; Steven J Kridel; Yong Q Chen
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Lack of mitochondria-generated acetyl-CoA by pyruvate dehydrogenase complex downregulates gene expression in the hepatic de novo lipogenic pathway.

Authors:  Saleh Mahmood; Barbara Birkaya; Todd C Rideout; Mulchand S Patel
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-10       Impact factor: 4.310

6.  Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.

Authors:  Lutfi Abu-Elheiga; Hongmei Wu; Ziwei Gu; Rubin Bressler; Salih J Wakil
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 7.  Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease.

Authors:  Anand R Saran; Shravan Dave; Amir Zarrinpar
Journal:  Gastroenterology       Date:  2020-02-13       Impact factor: 22.682

Review 8.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

9.  Chronic suppression of acetyl-CoA carboxylase 1 in beta-cells impairs insulin secretion via inhibition of glucose rather than lipid metabolism.

Authors:  Sarah M Ronnebaum; Jamie W Joseph; Olga Ilkayeva; Shawn C Burgess; Danhong Lu; Thomas C Becker; A Dean Sherry; Christopher B Newgard
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

10.  High Dietary Selenium Intake Alters Lipid Metabolism and Protein Synthesis in Liver and Muscle of Pigs.

Authors:  Zeping Zhao; Matthew Barcus; Jonggun Kim; Krystal L Lum; Courtney Mills; Xin Gen Lei
Journal:  J Nutr       Date:  2016-07-27       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.